China allows limited use of COVID-19 vaccine CanSino for their military after clinical trials shows its effectiveness

The vaccine has been approved for a period of one year after clinical trials proved it was safe and showed some efficacy.

Reuters July 01, 2020 09:41:06 IST
China allows limited use of COVID-19 vaccine CanSino for their military after clinical trials shows its effectiveness

China’s military has received the green light to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said on Monday.

The Ad5-nCoV is one of China’s eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus. The shot also won approval for human testing in Canada.

China allows limited use of COVID19 vaccine CanSino for their military after clinical trials shows its effectiveness

he Ad5-nCoV is one of China’s eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus. Image credit: CanSino Biologicals

China’s Central Military Commission approved the use of the vaccine by the military on 25 June for a period of one year, CanSino said in a filing. The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS).

“The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department,” CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.

CanSino declined to disclose whether the inoculation of the vaccine candidate is mandatory or optional, citing commercial secrets, in an email to Reuters.

The military approval follows China’s decision earlier this month to offer two other vaccine candidates to employees at state-owned firms travelling overseas.

The Phase 1 and 2 clinical trials of the CanSino’s vaccine candidate showed it has the potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success cannot be guaranteed, the company said.

Separately, AMS received an approval earlier this month to test its second experimental coronavirus vaccine in humans.

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

New case study suggests COVID-19 can lead to sudden permanent loss of hearing
Health

New case study suggests COVID-19 can lead to sudden permanent loss of hearing

Experts suggest that it may be a combination of the infection as well as the inflammation caused due to the virus in the ear that may be responsible for sensorineural hearing loss in COVID-19 patients

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, gets DCGI nod for Phase 3 trials
India

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, gets DCGI nod for Phase 3 trials

The phase 3 trials will be conducted in 19 sites across 10 states, including in cities such as Delhi, Mumbai, Patna and Lucknow and would seek to enroll 28,500 volunteers aged 18 years and above.

Daily COVID-19 recoveries exceed new cases; study finds 31% young adults faced anxiety during lockdown
India

Daily COVID-19 recoveries exceed new cases; study finds 31% young adults faced anxiety during lockdown

As COVID-19 cases continued to rise in Maharashtra, former chief minister Devendra Fadnavis announced on Saturday said that he had tested positive for the novel coronavirus